KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) Enterprise Value (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Enterprise Value for 18 consecutive years, with -$8.8 billion as the latest value for Q1 2026.

  • For Q1 2026, Enterprise Value fell 4.84% year-over-year to -$8.8 billion; the TTM value through Mar 2026 reached -$8.8 billion, down 4.84%, while the annual FY2025 figure was -$8.6 billion, 4.52% up from the prior year.
  • Enterprise Value hit -$8.8 billion in Q1 2026 for Regeneron Pharmaceuticals, down from -$8.6 billion in the prior quarter.
  • Across five years, Enterprise Value topped out at -$7.0 billion in Q3 2022 and bottomed at -$10.8 billion in Q4 2023.
  • Average Enterprise Value over 5 years is -$8.8 billion, with a median of -$8.8 billion recorded in 2026.
  • Year-over-year, Enterprise Value plummeted 101.23% in 2022 and then rose 23.85% in 2025.
  • Regeneron Pharmaceuticals' Enterprise Value stood at -$7.7 billion in 2022, then tumbled by 40.07% to -$10.8 billion in 2023, then increased by 16.9% to -$9.0 billion in 2024, then grew by 4.52% to -$8.6 billion in 2025, then decreased by 1.73% to -$8.8 billion in 2026.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$8.8 billion, -$8.6 billion, and -$8.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.